Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, W.-G.
Right arrow Articles by Otterson, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, W.-G.
Right arrow Articles by Otterson, G. A.
[Cancer Research 61, 1327-1333, February 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

DNA Methyltransferase Inhibition Enhances Apoptosis Induced by Histone Deacetylase Inhibitors1

Wei-Guo Zhu, Romola R. Lakshmanan, Matthew D. Beal and Gregory A. Otterson2

Division of Hematology/Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210

Histone acetylation has long been associated with transcriptional activation, whereas conversely, deacetylation of histones is associated with gene silencing and transcriptional repression. Here we report that inhibitors of histone deacetylase (HDAC), depsipeptide and trichostatin A, induce apoptotic cell death in human lung cancer cells as demonstrated by DNA flow cytometry and Western immunoblot to detect cleavage of poly(ADP-ribose) polymerase. This HDAC inhibitorinduced apoptosis is greatly enhanced in the presence of the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine (DAC). The HDAC inhibitor-induced apoptosis appears to be p53 independent, because no change in apoptotic cell death was observed in H1299 cells that expressed exogenous wild-type p53 (H1299 cells express no endogenous p53 protein). To further investigate the mechanism of DAC-enhanced, HDAC inhibitor-induced apoptosis, we analyzed histone H3 and H4 acetylation by Western immunoblotting. Results showed that depsipeptide induced a dose-dependent acetylation of histones H3 and H4, which was greatly increased in DAC-pretreated cells. By analyzing the acetylation of specific lysine residues at the amino terminus of histone H4 (Ac-5, Ac-8, Ac-12, and Ac-16), we found that the enhancement of HDAC inhibitor-induced acetylation of histones in the DAC-pretreated cells was not lysine site specific. These results demonstrate that DNA methylation status is an important determinant of apoptotic susceptibility to HDAC inhibitors.




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
L.-P. Wu, X. Wang, L. Li, Y. Zhao, S. Lu, Y. Yu, W. Zhou, X. Liu, J. Yang, Z. Zheng, et al.
Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter
Mol. Cell. Biol., May 15, 2008; 28(10): 3219 - 3235.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Egger, A. M. Aparicio, S. G. Escobar, and P. A. Jones
Inhibition of Histone Deacetylation Does Not Block Resilencing of p16 after 5-Aza-2'-Deoxycytidine Treatment
Cancer Res., January 1, 2007; 67(1): 346 - 353.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Fouladi, W. L. Furman, T. Chin, B. B. Freeman III, L. Dudkin, C. F. Stewart, M. D. Krailo, R. Speights, A. M. Ingle, P. J. Houghton, et al.
Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report
J. Clin. Oncol., August 1, 2006; 24(22): 3678 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Zhao, S. Lu, L. Wu, G. Chai, H. Wang, Y. Chen, J. Sun, Y. Yu, W. Zhou, Q. Zheng, et al.
Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1.
Mol. Cell. Biol., April 1, 2006; 26(7): 2782 - 2790.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Banwell, D. P. MacCartney, M. Guy, A. E. Miles, M. R. Uskokovic, J. Mansi, P. M. Stewart, L. P. O'Neill, B. M. Turner, K. W. Colston, et al.
Altered nuclear receptor corepressor expression attenuates vitamin d receptor signaling in breast cancer cells.
Clin. Cancer Res., April 1, 2006; 12(7): 2004 - 2013.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. K. Mukhopadhyay, E. Weisberg, D. Gilchrist, R. Bueno, D. J. Sugarbaker, and M. T. Jaklitsch
Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non-Small-Cell Lung Cancer.
Ann. Thorac. Surg., March 1, 2006; 81(3): 1034 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ogawa, T. Hayashi, M. Tokunou, K. Nakachi, J. E. Trosko, C.-C. Chang, and N. Yorioka
Suberoylanilide Hydroxamic Acid Enhances Gap Junctional Intercellular Communication via Acetylation of Histone Containing Connexin 43 Gene Locus
Cancer Res., November 1, 2005; 65(21): 9771 - 9778.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. Bevins and S. G. Zimmer
It's About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells
Cancer Res., August 1, 2005; 65(15): 6957 - 6966.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. J. Xiao, Y. Huang, Z. Dai, W. Sadee, J. Chen, S. Liu, G. Marcucci, J. Byrd, J. M. Covey, J. Wright, et al.
Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 467 - 475.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Rudek, M. Zhao, P. He, C. Hartke, J. Gilbert, S. D. Gore, M. A. Carducci, and S. D. Baker
Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3906 - 3911.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. N. Bhalla
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood, February 1, 2005; 105(3): 959 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-H. Park, Y. Jung, T. Y. Kim, S. G. Kim, H.-S. Jong, J. W. Lee, D.-K. Kim, J.-S. Lee, N. K. Kim, T.-Y. Kim, et al.
Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation
Clin. Cancer Res., August 1, 2004; 10(15): 5271 - 5281.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W.-G. Zhu, T. Hileman, Y. Ke, P. Wang, S. Lu, W. Duan, Z. Dai, T. Tong, M. A. Villalona-Calero, C. Plass, et al.
5-Aza-2'-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation
J. Biol. Chem., April 9, 2004; 279(15): 15161 - 15166.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
W.-G. Zhu, K. Srinivasan, Z. Dai, W. Duan, L. J. Druhan, H. Ding, L. Yee, M. A. Villalona-Calero, C. Plass, and G. A. Otterson
Methylation of Adjacent CpG Sites Affects Sp1/Sp3 Binding and Activity in the p21Cip1 Promoter
Mol. Cell. Biol., June 15, 2003; 23(12): 4056 - 4065.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L.-T. Liu, H.-C. Chang, L.-C. Chiang, and W.-C. Hung
Histone Deacetylase Inhibitor Up-Regulates RECK to Inhibit MMP-2 Activation and Cancer Cell Invasion
Cancer Res., June 15, 2003; 63(12): 3069 - 3072.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. W. Mayo, C. E. Denlinger, R. M. Broad, F. Yeung, E. T. Reilly, Y. Shi, and D. R. Jones
Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis Involves the Transcriptional Activation of NF-{kappa}B through the Akt Pathway
J. Biol. Chem., May 23, 2003; 278(21): 18980 - 18989.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Henderson, M. Mizzau, G. Paroni, R. Maestro, C. Schneider, and C. Brancolini
Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)
J. Biol. Chem., March 28, 2003; 278(14): 12579 - 12589.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
X. Yu, Z. S. Guo, M. G. Marcu, L. Neckers, D. M. Nguyen, G. A. Chen, and D. S. Schrump
Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
J Natl Cancer Inst, April 3, 2002; 94(7): 504 - 513.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. A. Fecteau, J. Mei, and H.-C. R. Wang
Differential Modulation of Signaling Pathways and Apoptosis of ras-Transformed 10T1/2 Cells by the Depsipeptide FR901228
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 890 - 899.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.